A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma.
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms PHILEMON
- 27 Jun 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2019.
- 27 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2019.
- 06 Dec 2016 According to the results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology, accrual of 50 patients was completed in 12 months, June 2016.